Compare MESO & WT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MESO | WT |
|---|---|---|
| Founded | 2004 | 1985 |
| Country | Australia | United States |
| Employees | 81 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | N/A | 2011 |
| Metric | MESO | WT |
|---|---|---|
| Price | $15.06 | $15.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $17.08 |
| AVG Volume (30 Days) | 256.0K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | ★ 0.77% |
| EPS Growth | N/A | ★ 127.27 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $493,753,000.00 |
| Revenue This Year | $644.56 | $33.08 |
| Revenue Next Year | $38.70 | $7.39 |
| P/E Ratio | ★ N/A | $20.88 |
| Revenue Growth | N/A | ★ 15.43 |
| 52 Week Low | $9.61 | $7.47 |
| 52 Week High | $21.50 | $17.68 |
| Indicator | MESO | WT |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 37.87 |
| Support Level | $14.53 | $12.98 |
| Resistance Level | $17.42 | $17.39 |
| Average True Range (ATR) | 0.55 | 0.62 |
| MACD | -0.00 | -0.28 |
| Stochastic Oscillator | 41.82 | 0.00 |
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.